Patents Assigned to Orionis Biosciences, Inc.
  • Fibroblast binding agents and use thereof
    Patent number: 11896643
    Abstract: The present invention relates, in part, to agents that bind fibroblast activation protein (FAP) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the FAP binding agents and their use in the treatment of various diseases.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: February 13, 2024
    Assignee: Orionis Biosciences, Inc.
    Inventors: Nikolai Kley, Jan Tavernier, Anje Cauwels
  • CD8 binding agents
    Patent number: 11566072
    Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: January 31, 2023
    Assignees: Orionis Biosciences, Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Jan Tavernier, Lennart Zabeau, Erik Depla
  • PD-1 and PD-L1 binding agents
    Patent number: 11498966
    Abstract: The present invention relates, in part, to agents that bind PD-1 or PD-L1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the PD-1 or PD-L1 binding agents and their use in the treatment of various diseases.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: November 15, 2022
    Assignees: Orionis Biosciences Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Jan Tavernier, Lennart Zabeau, Erik Depla
  • Therapeutic interferon alpha 1 proteins
    Patent number: 11440943
    Abstract: The present invention relates, in part, to chimeric proteins or chimeric protein complexes, such as Fc-based chimeric protein complexes, comprising interferon alpha 1, or a variant thereof, and their use as therapeutic agents.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: September 13, 2022
    Assignees: Orionis Biosciences, Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Erik Depla, Lennart Zabeau, Jan Tavernier
  • Targeted engineered interferon and uses thereof
    Patent number: 10906985
    Abstract: The present invention relates, in part, to chimeric proteins comprising consensus interferon, or a variant thereof, and their use as therapeutic agents.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: February 2, 2021
    Assignees: Orionis Biosciences, Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Lennart Zabeau, Jan Tavernier